Abeona Therapeutics Inc. said it has initiated a strategic review, including a sale or merger of the company, in order to advance its business and maximize shareholder value.
The company retained Jefferies LLC as its financial adviser to help with the evaluation of its strategic options, which might also entail the partnering of its various clinical and preclinical programs.
The biopharmaceutical company's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, an inherited disease affecting the skin and other organs.
Abeona's clinical programs also include ABO-102 and ABO-101, AAV9-based gene therapies for types A and B of Sanfilippo syndrome, a rare autosomal recessive lysosomal storage disease.
